Pages that link to "Q33629439"
Jump to navigation
Jump to search
The following pages link to Influence of Sex/Gender and Race on Responses to Raltegravir Combined With Tenofovir-Emtricitabine in Treatment-Naive Human Immunodeficiency Virus-1 Infected Patients: Pooled Analyses of the STARTMRK and QDMRK Studies (Q33629439):
Displayed 4 items.
- Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial (Q41997312) (← links)
- Sex Differences in HIV Infection. (Q52674721) (← links)
- Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority Trial (Q56988548) (← links)
- Screening and Enrollment by Sex in HIV Clinical Trials in the United States (Q90348296) (← links)